SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes

CONCLUSIONThese results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes.FUNDINGMark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH awards UL1TR001102 and UL1TR002541-01); and by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases, 5P30AI060354).PMID:34196300 | DOI:10.1172/JCI148635

Source: Clinical Lung Cancer - July 1, 2021 Category: Cancer & Oncology Authors: Yijia Li Alexis M Schneider Arnav Mehta Moshe Sade-Feldman Kyle R Kays Matteo Gentili Nicole C Charland Anna Lk Gonye Irena Gushterova Hargun K Khanna Thomas J LaSalle Kendall M Lavin-Parsons Brendan M Lilley Carl L Lodenstein Kasidet Manakongtreecheep Ju Source Type: research